Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 2015 (2015), Article ID 857416, 10 pages
http://dx.doi.org/10.1155/2015/857416
Review Article

Predictive Markers for the Recurrence of Nonmuscle Invasive Bladder Cancer Treated with Intravesical Therapy

Department of Urology and Renal Transplantation, Nagasaki University Hospital, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan

Received 26 September 2015; Accepted 10 November 2015

Academic Editor: Ja Hyeon Ku

Copyright © 2015 Yasuyoshi Miyata and Hideki Sakai. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. Brausi, J. A. Witjes, D. Lamm et al., “A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group,” Journal of Urology, vol. 186, no. 6, pp. 2158–2167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Allard, P. Bernard, Y. Fradet, and B. Têtu, “The early clinical course of primary Ta and T1 bladder cancer: a proposed prognostic index,” British Journal of Urology, vol. 81, no. 5, pp. 692–698, 1998. View at Publisher · View at Google Scholar · View at Scopus
  3. M. S. Wosnitzer, J. Domingo-Domenech, M. Castillo-Martin et al., “Predictive value of microtubule associated proteins Tau and Stathmin in patients with nonmuscle invasive bladder cancer receiving adjuvant intravesical taxane therapy,” Journal of Urology, vol. 186, no. 5, pp. 2094–2100, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. T. Inamoto, K. Taniguchi, K. Takahara et al., “Intravesical administration of exogenous microRNA-145 as a therapy for mouse orthotopic human bladder cancer xenograft,” Oncotarget, vol. 6, no. 25, pp. 21628–21635, 2015. View at Publisher · View at Google Scholar
  5. A. M. Kamat and S. Porten, “Myths and mysteries surrounding bacillus Calmette-Guérin therapy for bladder cancer,” European Urology, vol. 65, no. 2, pp. 267–269, 2014. View at Publisher · View at Google Scholar · View at Scopus
  6. R. J. Sylvester, A. P. M. van der Meijden, and D. L. Lamm, “Intravesical bacillus Calmette-Guerin reduces the risk of progression in patients with superficial bladder cancer: a meta-analysis of the published results of randomized clinical trials,” Journal of Urology, vol. 168, no. 5, pp. 1964–1970, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. A. M. Jackson, A. V. Ivshina, O. Senko et al., “Prognosis of intravesical Bacillus Calmette-Guérin therapy for superficial bladder cancer by immunological urinary measurements: statistically weighted syndromes analysis,” The Journal of Urology, vol. 159, no. 3, pp. 1054–1063, 1998. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Savic, I. Zlobec, G. N. Thalmann et al., “The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy,” International Journal of Cancer, vol. 124, no. 12, pp. 2899–2904, 2009. View at Publisher · View at Google Scholar · View at Scopus
  9. A. M. Kamat, D. L. Willis, R. J. Dickstein et al., “Novel fluorescence in situ hybridization-based definition of bacille Calmette-Guérin (BCG) failure for use in enhancing recruitment into clinical trials of intravesical therapies,” BJU International, 2015. View at Publisher · View at Google Scholar
  10. R. J. Cersosimo and W. K. Hong, “Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue,” Journal of Clinical Oncology, vol. 4, no. 3, pp. 425–439, 1986. View at Google Scholar · View at Scopus
  11. H. Araki, T. Mishina, K. Miyakoda, T. Fujiwara, and T. Kobayashi, “Cytosine arabinoside bladder instillation therapy for bladder tumors,” Tohoku Journal of Experimental Medicine, vol. 136, no. 1, pp. 23–28, 1982. View at Publisher · View at Google Scholar · View at Scopus
  12. P. A. Cockerill, J. J. Knoedler, I. Frank, R. Tarrell, and R. J. Karnes, “Intravesical gemcitabine in combination with mitomycin C as salvage treatment in recurrent non-muscle-invasive bladder cancer,” BJU International, 2015. View at Publisher · View at Google Scholar
  13. T. Kato, K. Nomura, F. Kondo, M. Wakisaka, and A. Komiya, “Analysis of Japanese patients treated with or without long term epirubicin plus Ara-C intravesical instillation therapy for low-grade superficial bladder cancer,” The Scientific World Journal, vol. 2015, Article ID 325305, 5 pages, 2015. View at Publisher · View at Google Scholar
  14. T. Okamura, R. Ando, H. Akita et al., “Prophylactic effects of Bacille Calmette-Guérin intravesical instillation therapy: time period-related comparison between Japan and Western countries,” Current Urology Reports, vol. 15, no. 1, article 374, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. I.-C. Cho, E. K. Kim, J. Y. Joung et al., “Adjuvant intravesical instillation for primary T1G3 bladder cancer: BCG versus MMC in Korea,” Anticancer Research, vol. 32, no. 4, pp. 1493–1498, 2012. View at Google Scholar · View at Scopus
  16. J. Palou, F. Algaba, I. Vera, O. Rodriguez, H. Villavicencio, and M. Sanchez-Carbayo, “Protein expression pattern of ezrin are predictors of progression in T1G3 bladder tumour treated with nonmaintenance Bacillus Calmette-Guérin,” European Urology, vol. 56, no. 5, pp. 829–836, 2009. View at Publisher · View at Google Scholar · View at Scopus
  17. H. K. Seo, K. S. Cho, J. Chung et al., “Prognostic value of p53 and Ki-67 expression in intermediate-risk patients with nonmuscle-invasive bladder cancer receiving adjuvant intravesical mitomycin C therapy,” Urology, vol. 76, no. 2, pp. 512.e1–512.e7, 2010. View at Publisher · View at Google Scholar · View at Scopus
  18. J.-X. Chen, N. Deng, X. Chen et al., “A novel molecular grading model: combination of Ki67 and VEGF in predicting tumor recurrence and progression in non-invasive urothelial bladder cancer,” Asian Pacific Journal of Cancer Prevention, vol. 13, no. 5, pp. 2229–2234, 2012. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Park, C. Song, E. Shin, J. H. Hong, C.-S. Kim, and H. Ahn, “Do molecular biomarkers have prognostic value in primary T1G3 bladder cancer treated with bacillus Calmette-Guérin intravesical therapy?” Urologic Oncology: Seminars and Original Investigations, vol. 31, no. 6, pp. 849–856, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. K. Esuvaranathan, E. Chiong, T. P. Thamboo et al., “Predictive value of p53 and pRb expression in superficial bladder cancer patients treated with BCG and interferon-alpha,” Cancer, vol. 109, no. 6, pp. 1097–1105, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. L. Cormio, I. Tolve, P. Annese et al., “Altered p53 and pRb expression is predictive of response to BCG treatment in T1G3 bladder cancer,” Anticancer Research, vol. 29, no. 10, pp. 4201–4204, 2009. View at Google Scholar · View at Scopus
  22. J. M. Gaya, J. M. López-Martínez, O. Karni-Schmidt et al., “ΔNp63 expression is a protective factor of progression in clinical high grade T1 bladder cancer,” Journal of Urology, vol. 193, no. 4, pp. 1144–1150, 2015. View at Publisher · View at Google Scholar · View at Scopus
  23. J. A. Karam, Y. Lotan, R. Ashfaq, A. I. Sagalowsky, and S. F. Shariat, “Survivin expression in patients with non-muscle-invasive urothelial cell carcinoma of the bladder,” Urology, vol. 70, no. 3, pp. 482–486, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. P. K. Jaiswal, A. Goel, A. Mandhani, and R. D. Mittal, “Functional polymorphisms in promoter survivin gene and its association with susceptibility to bladder cancer in North Indian cohort,” Molecular Biology Reports, vol. 39, no. 5, pp. 5615–5621, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. S. Shirotake, A. Miyajima, T. Kosaka et al., “Angiotensin II type 1 receptor expression and microvessel density in human bladder cancer,” Urology, vol. 77, no. 4, pp. 1009.e19–1009.e25, 2011. View at Publisher · View at Google Scholar · View at Scopus
  26. C. Cheng, F. S. Varn, and C. J. Marsit, “E2F4 program is predictive of progression and intravesical immunotherapy efficacy in bladder cancer,” Molecular Cancer Research, vol. 13, no. 9, pp. 1316–1324, 2015. View at Publisher · View at Google Scholar
  27. P. A. Videira, F. M. Calais, M. Correia et al., “fficacy of Bacille-Calmette-Guérin immunotherapy predict by expression of antigen-presenting molecules and chemokines,” Urology, vol. 74, no. 4, pp. 944–949, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. C. Ayari, H. LaRue, H. Hovington et al., “Bladder tumor infiltrating mature dendritic cells and macrophage as predictor of response to Bacillus Calmette-Guérin immunotherapy,” European Urology, vol. 55, no. 6, pp. 1386–1396, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Takayama, K. Nishimura, A. Tsujimura et al., “Increased infiltration of tumor associated with poor prognosis of bladder carcinoma in situ after intravesical Bacillus Calmette-Guerin instillation,” Journal of Urology, vol. 181, no. 4, pp. 1894–1900, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. R. Nunez-Nateras, E. P. Castle, C. A. Protheroe et al., “Predicting response to bacillus Calmette-Guérin (BCG) in patients with carcinoma in situ of the bladder,” Urologic Oncology, vol. 32, no. 1, pp. 45.e23–45.e30, 2014. View at Publisher · View at Google Scholar · View at Scopus
  31. F. Saint, L. Salomon, R. Quintela et al., “Do prognostic parameters of remission versus relapse after Bacillus Calmette–Guérin (BCG) immunotherapy exist?: analysis of a quarter century of literature,” European Urology, vol. 43, no. 4, pp. 351–361, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. H. W. Herr, T. N. Milan, and G. Dalbagni, “BCG-refractory vs. BCG-relapsing non-muscle-invasive bladder cancer: a prospective cohort outcomes study,” Urologic Oncology, vol. 33, no. 3, pp. 108.e1–108.e4, 2015. View at Publisher · View at Google Scholar
  33. L. Nakopoulou, C. Vourlakou, A. Zervas, A. Tzonou, H. Gakiopoulou, and M.-A. Dimopoulos, “The prevalence of bcl-2, p53, and Ki-67 immunoreactivity in transitional cell bladder carcinomas and their clinicopathologic correlates,” Human Pathology, vol. 29, no. 2, pp. 146–154, 1998. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Miyata, S. Kanda, K. Mitsunari, A. Asai, and H. Sakai, “Heme oxygenase-1 expression is associated with tumor aggressiveness and outcomes in patients with bladder cancer: a correlation with smoking intensity,” Translational Research, vol. 164, no. 6, pp. 468–476, 2014. View at Publisher · View at Google Scholar · View at Scopus
  35. A. R. Zlotta, J.-C. Noel, I. Fayt et al., “Correlation and prognostic significance of p53, p21WAF1/CIP1 and Ki-67 expression in patients with superficial bladder tumors treated with bacillus Calmette-Guerin intravesical therapy,” Journal of Urology, vol. 161, no. 3, pp. 792–798, 1999. View at Publisher · View at Google Scholar · View at Scopus
  36. T. Lebret, V. Becette, J.-M. Hervé et al., “Prognostic value of MIB-1 antibody labeling index to predict response to Bacillus Calmette-Guerin therapy in a high-risk selected population of patients with stage T1 grade G3 bladder cancer,” European Urology, vol. 37, no. 6, pp. 654–659, 2000. View at Publisher · View at Google Scholar · View at Scopus
  37. T. Okamura, H. Akita, N. Kawai, K. Tozawa, Y. Yamada, and K. Kohri, “Immunohistochemical evaluation of p53, proliferating cell nuclear antigen (PCNA) and bcl-2 expression during bacillus calmette-guerin (BCG) intravesical instillation therapy for superficial bladder cancers,” Urological Research, vol. 26, no. 3, pp. 161–164, 1998. View at Publisher · View at Google Scholar · View at Scopus
  38. R. S. Dipaola and E. C. Lattime, “Bacillus Calmette-Guerin mechanism of action: the role of immunity, apoptosis, necrosis and autophagy,” Journal of Urology, vol. 178, no. 5, pp. 1840–1841, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. Y. Miyata, K. Mitsunari, A. Akihiro, S. Watanabe, Y. Mochizuki, and H. Sakai, “Smoking-induced changes in cancer-related factors in patients with upper tract urothelial cancer,” Molecular and Clinical Oncology, vol. 3, no. 2, pp. 287–294, 2015. View at Publisher · View at Google Scholar
  40. Y. Miyata, S. Kanda, H. Sakai, and P. A. Greer, “Feline sarcoma-related protein expression correlates with malignant aggressiveness and poor prognosis in renal cell carcinoma,” Cancer Science, vol. 104, no. 6, pp. 681–686, 2013. View at Publisher · View at Google Scholar · View at Scopus
  41. R. D. Bonfil, A. D. Gonzalez, D. Siguelboim et al., “Immunohistochemical analysis of Ki-67, p21waf1/cip1 and apoptosis in marker lesions from patients with superficial bladder tumours treated with vinorelbine intravesical therapy in a preliminary phase I trial,” BJU International, vol. 88, no. 4, pp. 425–431, 2001. View at Publisher · View at Google Scholar · View at Scopus
  42. A. W. Hitchings, M. Kumar, S. Jordan, V. Nargund, J. Martin, and D. M. Berney, “Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb,” British Journal of Cancer, vol. 91, no. 3, pp. 552–557, 2004. View at Publisher · View at Google Scholar
  43. H. Ovesen, T. Horn, and K. Steven, “Long-term efficacy of intravesical bacillus Calmette-Guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation,” Journal of Urology, vol. 157, no. 5, pp. 1655–1659, 1997. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Caliskan, L. N. Türkeri, B. Mansuroglu et al., “Nuclear accumulation of mutant p53 protein: a possible predictor of failure of intravesical therapy in bladder cancer,” British Journal of Urology, vol. 79, no. 3, pp. 373–377, 1997. View at Publisher · View at Google Scholar · View at Scopus
  45. F. Pages, T. A. Flam, A. Vieillefond et al., “p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors,” Journal of Urology, vol. 159, no. 3, pp. 1079–1084, 1998. View at Publisher · View at Google Scholar · View at Scopus
  46. C. Pfister, J. M. Flaman, F. Dunet, P. Grise, and T. Frebourg, “T53 mutation in bladder tumors inactivate the transactivation of the P21 and BAX genes, and have a predictive value for the clinical outcome after Bacillus Calmette-Guérin therapy,” The Journal of Urology, vol. 162, no. 1, pp. 69–73, 1999. View at Publisher · View at Google Scholar
  47. X. Zhou, G. Zhang, Y. Tian, and M. Seno, “p53 Status correlates with the risk of recurrence in non-muscle invasive bladder cancers treated with Bacillus Calmette-Guérin: a meta-analysis,” PLoS ONE, vol. 10, no. 3, Article ID e0119476, 2015. View at Publisher · View at Google Scholar
  48. A. Yang, M. Kaghad, Y. Wang et al., “p63, a p53 homolog at 3q27–29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities,” Molecular Cell, vol. 2, no. 3, pp. 305–316, 1998. View at Publisher · View at Google Scholar · View at Scopus
  49. M. J. Urist, C. J. Di Como, M.-L. Lu et al., “Loss of p63 expression is associated with tumor progression in bladder cancer,” The American Journal of Pathology, vol. 161, no. 4, pp. 1199–1206, 2002. View at Publisher · View at Google Scholar · View at Scopus
  50. N. E. Buckley, S. J. Conlon, K. Jirstrom et al., “The ΔNp63 proteins are key allies of BRCA1 in the prevention of basal-like breast cancer,” Cancer Research, vol. 71, no. 5, pp. 1933–1944, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. D. C. Altieri, “Survivin, versatile modulation of cell division and apoptosis in cancer,” Oncogene, vol. 22, no. 53, pp. 8581–8589, 2003. View at Publisher · View at Google Scholar · View at Scopus
  52. S. F. Shariat, R. Ashfaq, P. I. Karakiewicz, O. Saeedi, A. I. Sagalowsky, and Y. Lotan, “Survivin expression is associated with bladder cancer presence, stage, progression, and mortality,” Cancer, vol. 109, no. 6, pp. 1106–1113, 2007. View at Publisher · View at Google Scholar · View at Scopus
  53. D. Ye, H. Li, S. Qian, Y. Sun, J. Zhang, and Y. Ma, “Bcl-2/bax expression and p53 gene status in human bladder cancer: relationship to early recurrence with intravesical chemotherapy after resection,” Journal of Urology, vol. 160, no. 6, pp. 2025–2029, 1998. View at Publisher · View at Google Scholar · View at Scopus
  54. F. Ajili, B. Kaabi, A. Darouiche et al., “Prognostic value of bcl-2 and Bax tumor cell expression in patients with non muscle-invasive bladder cancer receiving Bacillus Calmette-Guérin immunotherapy,” Ultrastructural Pathology, vol. 36, no. 1, pp. 31–39, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. Y. Miyata, S. Kanda, K. Ohba et al., “Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factors-A, -C, and -D,” Clinical Cancer Research, vol. 12, no. 3, part 1, pp. 800–806, 2006. View at Publisher · View at Google Scholar · View at Scopus
  56. A. P. Mitra, C. C. Bartsch, and R. J. Cote, “Strategies for molecular expression profiling in bladder cancer,” Cancer and Metastasis Reviews, vol. 28, no. 3-4, pp. 317–326, 2009. View at Publisher · View at Google Scholar · View at Scopus
  57. L. Santos, C. Costa, S. Pereira et al., “Neovascularisation is a prognostic factor of early recurrence in T1/G2 urothelial bladder tumours,” Annals of Oncology, vol. 14, no. 9, pp. 1419–1424, 2003. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Bartoletti, T. Cai, G. Nesi, I. Sardi, and M. Rizzo, “Qualitative and quantitative analysis of angiogenetic factors in transitional cell bladder carcinoma: relationship with clinical course at 10 years follow-up,” Oncology Reports, vol. 14, no. 1, pp. 251–255, 2005. View at Google Scholar · View at Scopus
  59. P. Mangeat, C. Roy, and M. Martin, “ERM proteins in cell adhesion and membrane dynamics,” Trends in Cell Biology, vol. 9, no. 5, pp. 187–192, 1999. View at Publisher · View at Google Scholar · View at Scopus
  60. K. Ohtani, H. Sakamoto, T. Rutherford, Z. Chen, K. Satoh, and F. Naftolin, “Ezrin, a membrane-cytoskeletal linking protein, is involved in the process of invasion of endometrial cancer cells,” Cancer Letters, vol. 147, no. 1-2, pp. 31–38, 1999. View at Publisher · View at Google Scholar · View at Scopus
  61. A. A. Bakkar, H. Wallerand, F. Radvanyi et al., “FGR3 and TP53 gene mutations define two distinct pathways in urothelial carcinoma of the bladder,” Cancer Research, vol. 63, no. 23, pp. 8108–8112, 2003. View at Google Scholar
  62. S. Hernández, E. López-Knowles, J. Lloreta et al., “FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis,” Clinical Cancer Research, vol. 11, no. 15, pp. 5444–5450, 2005. View at Publisher · View at Google Scholar · View at Scopus
  63. A. Lamy, F. Gobet, M. Laurent et al., “Molecular profiling of bladder tumors based on the detection of FGFR3 and TP53 mutations,” Journal of Urology, vol. 176, no. 6, part 1, pp. 2686–2689, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. K. S. Han, I. G. Jeong, J. Y. Joung et al., “Clinical value of PTEN in patients with superficial bladder cancer,” Urologia Internationalis, vol. 80, no. 3, pp. 264–269, 2008. View at Publisher · View at Google Scholar · View at Scopus
  65. P. Mhawech, F. Herrmann, M. Coassin, L. Guillou, and C. E. Iselin, “Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression,” Cancer, vol. 98, no. 8, pp. 1649–1657, 2003. View at Publisher · View at Google Scholar · View at Scopus
  66. C. A. Rentsch, F. D. Birkhäuser, C. Biot et al., “Bacillus calmette-guérin strain differences have an impact on clinical outcome in bladder cancer immunotherapy,” European Urology, vol. 66, no. 4, pp. 677–688, 2014. View at Publisher · View at Google Scholar · View at Scopus
  67. A. Sengiku, M. Ito, Y. Miyazaki, H. Sawazaki, T. Takahashi, and K. Ogura, “A prospective comparative study of intravesical bacillus Calmette-Guérin therapy with the tokyo or connaught strain for nonmuscle invasive bladder cancer,” Journal of Urology, vol. 190, no. 1, pp. 50–54, 2013. View at Publisher · View at Google Scholar · View at Scopus
  68. A. R. Zlotta, J. P. Van Vooren, K. Huygen et al., “What is the optimal regimen for BCG intravesical therapy? Are six weekly instillations necessary?” European Urology, vol. 37, no. 4, pp. 470–477, 2000. View at Publisher · View at Google Scholar · View at Scopus
  69. A. P. Lawton and M. Kronenberg, “The third way: progress on pathways of antigen processing and presentation by CD1,” Immunology and Cell Biology, vol. 82, no. 3, pp. 295–306, 2004. View at Publisher · View at Google Scholar · View at Scopus
  70. K. Ohba, Y. Miyata, S. Kanda, S. Koga, T. Hayashi, and H. Kanetake, “Expression of urokinase-type plasminogen activator, urokinase-type plasminogen activator receptor and plasminogen activator inhibitors in patients with renal cell carcinoma: correlation with tumor associated macrophage and prognosis,” Journal of Urology, vol. 174, no. 2, pp. 461–465, 2005. View at Publisher · View at Google Scholar · View at Scopus
  71. M. M. Boström, H. Irjala, T. Mirtti et al., “Tumor-associated macrophages provide significant prognostic information in urothelial bladder cancer,” PLoS ONE, vol. 10, no. 7, Article ID e0133552, 2015. View at Publisher · View at Google Scholar
  72. A. Nardin and J.-P. Abastado, “Macrophages and cancer,” Frontiers in Bioscience, vol. 13, no. 9, pp. 3494–3505, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. J. R. Sierra, S. Corso, L. Caione et al., “Tumor angiogenesis and progression are enhanced by Sema4D produced by tumor-associated macrophages,” The Journal of Experimental Medicine, vol. 205, no. 7, pp. 1673–1685, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. F. Suriano, D. Santini, G. Perrone et al., “Tumor associated macrophages polarization dictates the efficacy of BCG instillation in non-muscle invasive urothelial bladder cancer,” Journal of Experimental and Clinical Cancer Research, vol. 32, article 87, 2013. View at Publisher · View at Google Scholar · View at Scopus
  75. V. Yutkin, D. Pode, E. Pikarsky, and O. Mandelboim, “The expression level of ligands for natural killer cell receptors predicts response to Bacillus Calmette-Guérin therapy: a pilot study,” The Journal of Urology, vol. 178, no. 6, pp. 2660–2664, 2007. View at Publisher · View at Google Scholar · View at Scopus
  76. A. M. Kamat, J. Briggman, D. L. Urbauer et al., “Cytokine panel for response to intravesical therapy (CyPRIT): nomogram of changes in urinary cytokine levels predicts patient response to Bacillus Calmette-Guérin,” European Urology, 2015. View at Publisher · View at Google Scholar
  77. J. Klap, M. Schmid, and K. R. Loughlin, “Biomarkers in patients treated with BCG: an update,” Canadian Journal of Urology, vol. 21, no. 4, pp. 7335–7343, 2014. View at Google Scholar · View at Scopus
  78. P. Gros, E. Skamene, and A. Forget, “Genetic control of natural resistance to Mycobacterium bovis (BCG) in mice,” Journal of Immunology, vol. 127, no. 6, pp. 2417–2421, 1981. View at Google Scholar · View at Scopus
  79. R. Bellamy, C. Ruwende, T. Corrah, K. P. W. J. McAdam, H. C. Whittle, and A. V. S. Hill, “Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans,” The New England Journal of Medicine, vol. 338, no. 10, pp. 640–644, 1998. View at Publisher · View at Google Scholar · View at Scopus
  80. P.-S. Gao, S. Fujishima, X.-Q. Mao et al., “Genetic variants of NRAMP1 and active tuberculosis in Japanese populations,” Clinical Genetics, vol. 58, no. 1, pp. 74–76, 2000. View at Publisher · View at Google Scholar · View at Scopus
  81. M. Decobert, H. LaRue, A. Bergeron et al., “Polymorphisms of the human NRAMP1 gene are associated with response to Bacillus Calmette-Guerin immunotherapy for superficial bladder cancer,” Journal of Urology, vol. 175, no. 4, pp. 1506–1511, 2006. View at Publisher · View at Google Scholar · View at Scopus
  82. E. Chiong, A. Kesavan, R. Mahendran et al., “NRAMP1 and hGPX1 gene polymorphism and response to Bacillus Calmette-Guérin therapy for bladder cancer,” European Urology, vol. 59, no. 3, pp. 430–437, 2011. View at Publisher · View at Google Scholar · View at Scopus
  83. Y. Ichimura, T. Habuchi, N. Tsuchiya et al., “Increased risk of bladder cancer associated with a glutathione peroxidase 1 codon 198 variant,” Journal of Urology, vol. 172, no. 2, pp. 728–732, 2004. View at Publisher · View at Google Scholar · View at Scopus
  84. H. Zhao, D. Liang, H. B. Grossman, and X. Wu, “Glutathione peroxidase 1 gene polymorphism and risk of recurrence in patients with superficial bladder cancer,” Urology, vol. 66, no. 4, pp. 769–774, 2005. View at Publisher · View at Google Scholar · View at Scopus
  85. H. L. Ke, J. Lin, Y. Ye et al., “Genetic variations in glutathione pathway genes predict cancer recurrence in patients treated with transurethral resection and Bacillus Calmette-Guérin instillation for non-muscle invasive bladder cancer,” Annals of Surgical Oncology, vol. 22, no. 12, pp. 4104–4110, 2015. View at Publisher · View at Google Scholar